SE420718B - Sett att framstella nya dekapeptidamidderivat med ovalationsinducerande aktivitet - Google Patents

Sett att framstella nya dekapeptidamidderivat med ovalationsinducerande aktivitet

Info

Publication number
SE420718B
SE420718B SE7502520A SE7502520A SE420718B SE 420718 B SE420718 B SE 420718B SE 7502520 A SE7502520 A SE 7502520A SE 7502520 A SE7502520 A SE 7502520A SE 420718 B SE420718 B SE 420718B
Authority
SE
Sweden
Prior art keywords
decapeptidamide
ovalation
derivatives
inducing activity
make new
Prior art date
Application number
SE7502520A
Other languages
English (en)
Swedish (sv)
Other versions
SE7502520L (de
Inventor
M Fujino
T Fukuda
S Shinagawa
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of SE7502520L publication Critical patent/SE7502520L/xx
Publication of SE420718B publication Critical patent/SE420718B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/13—Luteinizing hormone-releasing hormone; related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE7502520A 1974-03-08 1975-03-06 Sett att framstella nya dekapeptidamidderivat med ovalationsinducerande aktivitet SE420718B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2744274A JPS5726506B2 (de) 1974-03-08 1974-03-08

Publications (2)

Publication Number Publication Date
SE7502520L SE7502520L (de) 1975-09-09
SE420718B true SE420718B (sv) 1981-10-26

Family

ID=12221217

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7502520A SE420718B (sv) 1974-03-08 1975-03-06 Sett att framstella nya dekapeptidamidderivat med ovalationsinducerande aktivitet

Country Status (18)

Country Link
US (1) US3972859A (de)
JP (1) JPS5726506B2 (de)
AT (1) AT348693B (de)
BE (1) BE826430A (de)
CA (1) CA1072953A (de)
CH (1) CH615661A5 (de)
CS (1) CS186284B2 (de)
DE (1) DE2509783C2 (de)
DK (1) DK149862C (de)
ES (1) ES435405A1 (de)
FI (1) FI60859C (de)
FR (1) FR2262995B1 (de)
GB (1) GB1498048A (de)
HU (1) HU174077B (de)
NL (1) NL181658C (de)
NO (1) NO145691C (de)
SE (1) SE420718B (de)
ZA (1) ZA751306B (de)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2438350C3 (de) * 1974-08-09 1979-06-13 Hoechst Ag, 6000 Frankfurt Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
AU497512B2 (en) * 1975-04-15 1978-12-14 Ici Australia Limited Nona and deca-peptides
US4215038A (en) * 1978-10-16 1980-07-29 The Salk Institute For Biological Studies Peptides which inhibit gonadal function
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
US4318905A (en) * 1980-06-23 1982-03-09 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide agonists of luteinizing hormone releasing hormone containing heterocyclic amino acid residues
ZA815447B (en) * 1980-08-29 1982-08-25 Salk Inst For Biological Studi Peptides affecting gonadal function
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
AU549053B2 (en) * 1981-12-28 1986-01-09 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
JPS58125819U (ja) * 1982-02-19 1983-08-26 名伸電機株式会社 積算電力量計用パツキン
US4581169A (en) * 1982-12-21 1986-04-08 Syntex (U.S.A.) Inc. Nona-peptide and deca-peptide analogs of LHRH, useful as LHRH antagonists
US4481190A (en) * 1982-12-21 1984-11-06 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
US4667014A (en) * 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4663435A (en) * 1982-12-06 1987-05-05 Merck & Co., Inc. Bridged cyclic hexapeptide somatostatin analogs
US4581168A (en) * 1983-02-21 1986-04-08 Sanofi Synthesis of hpGRF (Somatocrinin) in liquid phase and intermediate peptides
US4530920A (en) * 1983-11-07 1985-07-23 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
JP2653255B2 (ja) 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
CA2050425A1 (en) 1990-09-03 1992-03-04 Yoshiaki Uda Pharmaceutical composition and its mucous use
NZ240214A (en) 1990-10-16 1993-02-25 Takeda Chemical Industries Ltd Polymer compositions comprising a polylactic acid and a copolymer of glycolic acid and a hydroxycarboxylic acid; use as carrier for prolonged release pharmaceutical compositions of water soluble drugs
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
ES2110573T3 (es) 1992-08-07 1998-02-16 Takeda Chemical Industries Ltd Produccion de microcapsulas de farmacos solubles en agua.
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US20040259113A1 (en) * 1993-07-22 2004-12-23 Mayo Foundation For Medical Education And Research, Hybritech Incorporated Method for detection of metastatic prostate cancer
US5516639A (en) * 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
US6103237A (en) * 1993-07-22 2000-08-15 Hybritech Incorporated Stable variant hK2 polypeptide
CA2143044C (en) * 1994-02-21 2005-04-12 Yasutaka Igari Matrix for sustained-release preparation
EP0804593A1 (de) * 1994-05-10 1997-11-05 Mayo Foundation For Medical Education And Research Rekombinantes hk2 polypeptid
US6117455A (en) 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
NZ297157A (en) 1994-10-21 1999-08-30 Nps Pharma Inc Amine derivatives with calcium ion receptor activity; medicaments containing such compounds
US5837281A (en) 1995-03-17 1998-11-17 Takeda Chemical Industries, Ltd. Stabilized interface for iontophoresis
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
CA2192773C (en) 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
AU731146C (en) 1996-05-01 2005-02-03 Nps Pharmaceuticals, Inc. Inorganic ion receptor-active compounds
US5908400A (en) * 1996-06-20 1999-06-01 Hisamitsu Pharmaceutical Co., Inc. Device structure for iontophoresis
US6479263B1 (en) 1996-11-14 2002-11-12 Baylor College Of Medicine Method for detection of micrometastatic prostate cancer
US6235486B1 (en) 1997-06-20 2001-05-22 Mayo Foundation For Medical Education & Research Method for detection of breast cancer
US6737408B1 (en) 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
US6087128A (en) 1998-02-12 2000-07-11 Ndsu Research Foundation DNA encoding an avian E. coli iss
US6803448B1 (en) * 1998-07-22 2004-10-12 Vanderbilt University GBS toxin receptor
US8609614B2 (en) * 1998-07-22 2013-12-17 Vanderbilt University GBS toxin receptor compositions and methods of use
US6339062B1 (en) * 1998-11-23 2002-01-15 Inkine Pharmaceutical Company, Inc. Retroinverso polypeptides that mimic or inhibit thrombospondin activity
AUPR074500A0 (en) * 2000-10-13 2000-11-09 Monash University Treatment of t cell disorders
US20050020524A1 (en) * 1999-04-15 2005-01-27 Monash University Hematopoietic stem cell gene therapy
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
US20050042679A1 (en) * 1999-04-15 2005-02-24 Monash University Diagnostic indicator of thymic function
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
US20040241842A1 (en) * 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
US20040259803A1 (en) * 1999-04-15 2004-12-23 Monash University Disease prevention by reactivation of the thymus
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
EP1203014B1 (de) * 1999-08-06 2004-10-13 Genentech, Inc. Peptidantagonisten des faktors viia
US6407211B1 (en) * 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
ES2270893T3 (es) 1999-12-24 2007-04-16 Genentech, Inc. Procedimiento y composiciones para prolongar la vida media de compuestos bioactivos.
US20060228364A1 (en) * 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
EP1757311B1 (de) 1999-12-24 2009-02-11 Genentech, Inc. Verfahren und Zusammensetzungen zur Verlängerung der Entsorgungshalbwertszeit von biowirksamen Verbindungen
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20060088512A1 (en) * 2001-10-15 2006-04-27 Monash University Treatment of T cell disorders
US7164002B2 (en) 2002-02-06 2007-01-16 Genentech, Inc. FVIIa antagonists
CN100475271C (zh) 2003-08-20 2009-04-08 加利福尼亚大学董事会 具有抑制生长激素释放活性的促生长素抑制素类似物
CN101048425B (zh) * 2003-09-18 2012-12-26 雷文生物技术公司 Kid3及与其结合的kid3抗体
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
JP4390568B2 (ja) * 2004-01-19 2009-12-24 富士通株式会社 遅延測定システム
KR101295139B1 (ko) * 2004-06-07 2013-08-12 레이븐 바이오테크놀로지스, 인코퍼레이티드 트랜스페린 리셉터 항체
BRPI0516577A (pt) * 2004-10-05 2008-09-16 Genentech Inc agentes terapêuticos com toxicidade diminuìda
US7687242B2 (en) * 2005-01-12 2010-03-30 Raven Biotechnologies, Inc. KID31 and antibodies that bind thereto
JP2008538173A (ja) * 2005-01-31 2008-10-16 レイベン バイオテクノロジーズ，インコーポレイティド Ｌｕｃａ２およびそれに結合する抗体
WO2006084075A2 (en) 2005-02-02 2006-08-10 Raven Biotechnologies, Inc. Adam-9 modulators
US20060171952A1 (en) * 2005-02-02 2006-08-03 Mather Jennie P JAM-3 and antibodies that bind thereto
EP1846455A4 (de) * 2005-02-03 2010-02-17 Raven Biotechnologies Inc Antikörper gegen den onkostatin-m-rezeptor
EP1790656A1 (de) * 2005-11-25 2007-05-30 Nanokem S.A. Lösungsphasesynthese von Leuprolid
US20070197445A1 (en) * 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
WO2008066691A2 (en) * 2006-11-08 2008-06-05 Macrogenics West, Inc. Tes7 and antibodies that bind thereto
ES2414879T4 (es) 2009-04-20 2013-10-30 Allergan, Inc. Hidrogeles de fibroína de seda y usos de éstos
PL219569B1 (pl) 2010-02-19 2015-05-29 Peptaderm Spółka Z Ograniczoną Odpowiedzialnością Cykliczne tetrapeptydy i ich zastosowanie
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
ME03447B (de) 2010-03-04 2020-01-20 Macrogenics Inc Mit b7-h3 reagierende antikörper, immunologisch wirkende fragmente davon und verwendungen davon
MX369220B (es) 2011-05-21 2019-10-31 Macrogenics Inc Moleculas que enlazan cd3 capaces de enlazar a cd3 humano y no humano.
EP2557163A1 (de) 2011-08-12 2013-02-13 SymbioGruppe GmbH & Co KG Bakteriell gebildetes Mikrocin S, ein neues antimikrobielles Peptid, das gegen pathogene Mikroorganismen wirkt, z.B. enterohämorrhagisches Eschericha Coli (EHEC)
KR20140068087A (ko) 2011-08-23 2014-06-05 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 펩티드 나노입자 및 이의 용도
CN107090028A (zh) 2011-08-30 2017-08-25 梅约医学教育与研究基金会 利钠多肽
US9611305B2 (en) 2012-01-06 2017-04-04 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
BR112015022790A8 (pt) 2013-03-14 2020-01-21 Univ Duke molécula biespecífica, composição farmacêutica, método de tratamento de uma infecção por vírus latente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus persistente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus inativo em um indivíduo em necessidade de tal tratamento, método para exterminar uma célula que contém um genoma viral, e, método para exterminar uma célula que expressa uma proteína viral
CA2911613A1 (en) 2013-03-29 2014-10-02 Centre National De La Recherche Scientifique (Cnrs) Cgrp receptor agonist for hiv treatment or prevention
WO2015184207A1 (en) 2014-05-29 2015-12-03 Macrogenics, Inc. Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
SG11201702544WA (en) 2014-09-29 2017-04-27 Univ Duke Bispecific molecules comprising an hiv-1 envelope targeting arm
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
IL287916B2 (en) 2015-07-30 2023-09-01 Macrogenics Inc Molecules that bind pd-1 and methods of using them
KR20250079249A (ko) 2015-10-08 2025-06-04 마크로제닉스, 인크. 암 치료를 위한 조합 치료법
KR102815803B1 (ko) 2015-12-02 2025-06-05 주식회사 에스티사이언스 당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
SG11201804839WA (en) 2015-12-14 2018-07-30 Macrogenics Inc Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
WO2017180813A1 (en) 2016-04-15 2017-10-19 Macrogenics, Inc. Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
US10111929B1 (en) 2017-04-07 2018-10-30 Ez Ip, Llc Growth hormone releasing factor analogs and uses
US20220411511A1 (en) 2019-09-26 2022-12-29 Stcube & Co. Antibodies specific to glycosylated ctla-4 and methods of use thereof
KR20220088438A (ko) 2019-10-09 2022-06-27 주식회사 에스티큐브앤컴퍼니 글리코실화된 lag3에 대해 특이적인 항체 및 이의 사용 방법
US11596665B2 (en) 2020-06-23 2023-03-07 Chanda Zaveri Skin lightening formulations
US11951203B2 (en) 2020-08-26 2024-04-09 Chanda Zaveri Deep wrinkle vanishing compositions
US11793746B2 (en) 2020-10-01 2023-10-24 Chanda Zaveri Intense skin hydration systems and methods
US20220110852A1 (en) 2020-10-14 2022-04-14 Chanda Zaveri Pigment Stabilizers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3835108A (en) * 1972-02-15 1974-09-10 American Home Prod Process for preparing the releasing hormone of luteinizing hormone(lh)and of follicle stimulating hormone(fsh),salts and compositions thereof,and intermediates therefor
US3896104A (en) * 1974-05-22 1975-07-22 American Home Prod P-glu-his-trp-ser-tyr-d-lys-leu-arg-pro-gly-nh' 2 'and intermediates

Also Published As

Publication number Publication date
NO145691C (no) 1982-05-12
FI750682A7 (de) 1975-09-09
ZA751306B (en) 1976-01-28
HU174077B (hu) 1979-10-28
GB1498048A (en) 1978-01-18
FR2262995B1 (de) 1978-07-28
DK149862C (da) 1987-06-15
JPS50121277A (de) 1975-09-23
DK149862B (da) 1986-10-13
ATA138075A (de) 1978-07-15
CS186284B2 (en) 1978-11-30
US3972859A (en) 1976-08-03
JPS5726506B2 (de) 1982-06-04
CA1072953A (en) 1980-03-04
NO750763L (de) 1975-09-09
AU7859475A (en) 1976-08-26
CH615661A5 (de) 1980-02-15
FI60859B (fi) 1981-12-31
DE2509783C2 (de) 1983-02-17
NL181658B (nl) 1987-05-04
SE7502520L (de) 1975-09-09
AT348693B (de) 1979-02-26
NO145691B (no) 1982-02-01
FR2262995A1 (de) 1975-10-03
NL7502564A (nl) 1975-09-10
BE826430A (fr) 1975-09-08
DE2509783A1 (de) 1975-09-11
FI60859C (fi) 1982-04-13
DK92775A (de) 1975-09-09
NL181658C (nl) 1987-10-01
ES435405A1 (es) 1976-12-01

Similar Documents

Publication Publication Date Title
SE420718B (sv) Sett att framstella nya dekapeptidamidderivat med ovalationsinducerande aktivitet
SE420717B (sv) Sett att framstella nya nonapeptidamidderivat med ovulationsinducerande aktivitet
SE397520B (sv) Sett att framstella nya nonapeptidamidderivat med ovulationsinducerande aktivitet
SE401822B (sv) Sett att framstella nya nonapeptidamidderivat med ovulationsinducerande aktivitet
SE7508101L (sv) Sett att framstella nya kinazolinderivat med terapeutisk verkan.
SE425244B (sv) Sett att framstella 4-hydroxi-3-kinolin-karboxamidderivat
SE7711848L (sv) Sett att framstella nya 5-metyl-7-hydroxi-isoflavonderivat
SE410600B (sv) Sett att framstella nya arylaminopyrimidinderivat
SE417507B (sv) Sett att framstella 2-arylamino-2-imidazolinderivat
SE427108B (sv) Sett att framstella nya substituerade fenylettiksyror med inflammationshemmande verkan
SE408300B (sv) Sett att framstella nya dipeptidderivat
SE7505974L (sv) Nya foreningar med ergolinskelett jemte sett att framstella dem
SE7602729L (sv) Sett att framstella nya indolylalkylpiperidiner
SE420602B (sv) Sett att framstella pyrazin-3-metoxi-2-karboxamidderivat
SE7511328L (sv) Sett att framstella nya pyridinderivat
SE424991B (sv) Sett att framstella nya 5-fenyl-oxazolidinoner
SE427655B (sv) Sett att framstella abietamidderivat
SE7509209L (sv) Sett att framstella nya kinolinderivat
SE415252B (sv) Sett att framstella nya oxifenylbutazonderivat
SE412233B (sv) Sett att framstella nya fenotiazinderivat
SE7609666L (sv) Sett att framstella nya 5-aminometyltiazolderivat
SE428471B (sv) Sett att framstella imidazolderivat
SE7505711L (sv) Nya tiofenderivat och sett att framstella desamma
SE7506571L (sv) Sett att framstella nya bufatrienolidramnosideter
SE439303B (sv) Sett att framstella nya aminoetanolderivat

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 7502520-5

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 7502520-5

Format of ref document f/p: F